CoChat

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Significance Statement: Studies of renin-angiotensin system inhibitors have consistently shown that the magnitude of albuminuria reduction during the first months of treatment is associated with risk reduction for kidney and cardiovascular outcomes. Whether or not the association between early changes in albuminuria and these outcomes also occurs with sodium-glucose cotransporter 2 (SGLT2) inhibition is unclear. This post hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that, in people with type 2 diabetes and CKD, treatment with the SGLT2 inhibitor canagliflozin results in an early and sustained reduction in albuminuria. It also shows that early changes in albuminuria were independently associated with long-term kidney and cardiovascular outcomes. These findings highlight the importance of monitoring albuminuria during canagliflozin treatment to assess kidney and cardiovascular prognosis. Background: The association between early changes in albuminuria and kidney and cardiovascular events is primarily based on trials of renin-angiotensin system blockade. It is unclear whether this association occurs with sodium-glucose cotransporter 2 inhibition. Methods: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial enrolled 4401 patients with type 2 diabetes and CKD (urinary albumin-creatinine ratio [UACR] >300 mg/g). This post hoc analysis assessed canagliflozin’s effect on albuminuria and how early change in albuminuria (baseline to week 26) is associated with the primary kidney outcome (ESKD, doubling of serum creatinine, or kidney death), major adverse cardiovascular events, and hospitalization for heart failure or cardiovascular death. Results: Complete data for early change in albuminuria and other covariates were available for 3836 (87.2%) participants in the CREDENCE trial. Compared with placebo, canagliflozin lowered UACR by 31% (95% confidence interval [95% CI], 27% to 36%) at week 26, and significantly increased the likelihood of achieving a 30% reduction in UACR (odds ratio, 2.69; 95% CI, 2.35 to 3.07). Each 30% decrease in UACR over the first 26 weeks was independently associated with a lower hazard for the primary kidney outcome (hazard ratio [HR], 0.71; 95% CI, 0.67 to 0.76; P <0.001), major adverse cardiovascular events (HR, 0.92; 95% CI, 0.88 to 0.96; P <0.001), and hospitalization for heart failure or cardiovascular death (HR, 0.86; 95% CI, 0.81 to 0.90; P <0.001). Residual albuminuria levels at week 26 remained a strong independent risk factor for kidney and cardiovascular events, overall and in each treatment arm. Conclusions: In people with type 2 diabetes and CKD, use of canagliflozin results in early, sustained reductions in albuminuria, which were independently associated with long-term kidney and cardiovascular outcomes.

Overview

Integrity signals

Registry

Crossref · 10.1681/asn.2020050723

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 184

Metadata

Authors
Oshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., De Nicola, L., Pollock, C., Rosenthal, N., Wheeler, D. C., Jardine, M. J., & Heerspink, H. J. L.
Affiliations
  • Kanazawa University (JP)
  • UNSW Sydney (AU)
  • NYU Langone Health (US)
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
  • Janssen Research & Development (United States) (US)
  • University of Utah (US)
  • University of British Columbia (CA)
  • Stanford Medicine (US)
  • Department of Advanced Medical and Surgical Sciences, Nephrology and Dialysis Unit, University Vanvitelli, Naples, Italy
  • The University of Sydney (AU)
  • Concord Repatriation General Hospital (AU)
  • University Medical Center Groningen (NL)
Venue
Journal of the American Society of Nephrology
Published
2020-09-30
Volume
31
Issue
12
Pages
2925-2936
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W3089612515
Cited by
176
References
27
Citations by year
2026: 23 · 2025: 26 · 2024: 39 · 2023: 45 · 2022: 18 · 2021: 23 · 2020: 2
FWCI
13.83
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • Journal of the American Society of Nephrology (publishedVersion, public-domain)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
  • Janssen Research and Development
  • Janssen Scientific Affairs, LLC
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
canagliflozin, SGLT2 inhibitors, albuminuria, urinary albumin-creatinine ratio, type 2 diabetes, chronic kidney disease, early treatment response, renal outcomes, cardiovascular outcomes, heart failure hospitalization, CREDENCE trial, prognostic factors, end-stage renal disease, cardiovascular mortality, renal function decline
MeSH terms
Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Aged, Albuminuria, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. https://app.cochat.ai/papers/10.1681/asn.2020050723
The paper
Oshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., De Nicola, L., Pollock, C., Rosenthal, N., Wheeler, D. C., Jardine, M. J., & Heerspink, H. J. L. (2020). Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2020050723

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.